AP2013007045A0 - 6-Cyclobutyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives their use as PDE9A inhibitors - Google Patents

6-Cyclobutyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives their use as PDE9A inhibitors

Info

Publication number: AP2013007045A0
Authority: AP; ARIPO
Prior art keywords: pyrazolo; pyrimidin; cyclobutyl; dihydro; derivatives
Prior art date: 2011-02-14

Application number

AP2013007045A

Other languages

English (en)

Inventor

Niklas Heine

Riccardo Giovannini

Marco Ferrara

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-14

Filing date

2012-02-13

Publication date

2013-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46671960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013007045(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-02-13 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2013-08-31 Publication of AP2013007045A0 publication Critical patent/AP2013007045A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AP2013007045A 2011-02-14 2012-02-13 6-Cyclobutyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives their use as PDE9A inhibitors AP2013007045A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11154397		2011-02-14
PCT/EP2012/052378 WO2012110440A1 (en)	2011-02-14	2012-02-13	6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors

Publications (1)

Publication Number	Publication Date
AP2013007045A0 true AP2013007045A0 (en)	2013-08-31

Family

ID=46671960

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2013007045A AP2013007045A0 (en)	2011-02-14	2012-02-13	6-Cyclobutyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives their use as PDE9A inhibitors

Country Status (23)

Country	Link
US (1)	US20130040971A1 (xx)
EP (1)	EP2675807B1 (xx)
JP (1)	JP2014505091A (xx)
KR (1)	KR20140010036A (xx)
CN (1)	CN103459397A (xx)
AP (1)	AP2013007045A0 (xx)
AR (1)	AR085219A1 (xx)
AU (1)	AU2012217208A1 (xx)
BR (1)	BR112013020605A2 (xx)
CA (1)	CA2827261A1 (xx)
CL (1)	CL2013002341A1 (xx)
CO (1)	CO6791616A2 (xx)
EA (1)	EA023574B1 (xx)
EC (1)	ECSP13012852A (xx)
IL (1)	IL227526A0 (xx)
MA (1)	MA34889B1 (xx)
MX (1)	MX2013009343A (xx)
PE (1)	PE20140970A1 (xx)
PH (1)	PH12013501677A1 (xx)
SG (1)	SG192756A1 (xx)
TN (1)	TN2013000324A1 (xx)
TW (1)	TW201245199A (xx)
WO (1)	WO2012110440A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
KR101052122B1 (ko)	2005-10-25	2011-07-26	시오노기세야쿠 가부시키가이샤	아미노디히드로티아진 유도체
EP2147914B1 (en)	2007-04-24	2014-06-04	Shionogi&Co., Ltd.	Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en)	2007-04-24	2011-09-14	Shionogi & Co	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
UA105362C2 (xx)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	Похідні 1-гетероцикліл-1,5-дигідропіразоло$3,4-d]піримідин-4-ону та їх застосування як модулятори pde9a$производные 1-гетероциклил-1,5-дигидропиразоло$3,4-d] пиримидин-4-она и их применение в качестве модуляторов pde9a
MX2010013256A (es)	2008-06-13	2010-12-21	Shionogi & Co	Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa.
JPWO2010047372A1 (ja)	2008-10-22	2012-03-22	塩野義製薬株式会社	Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
AU2010230290B2 (en)	2009-03-31	2013-03-14	Boehringer Ingelheim International Gmbh	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators
JPWO2011071135A1 (ja)	2009-12-11	2013-04-22	塩野義製薬株式会社	オキサジン誘導体
EP2634188A4 (en)	2010-10-29	2014-05-07	Shionogi & Co	FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
CA2816285A1 (en)	2010-10-29	2012-05-03	Shionogi & Co., Ltd.	Naphthyridine derivative
TW201247635A (en)	2011-04-26	2012-12-01	Shionogi & Co	Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
JP2016501827A (ja)	2012-10-24	2016-01-21	塩野義製薬株式会社	Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
CN105669680B (zh) *	2016-03-24	2018-02-23	南京药捷安康生物科技有限公司	吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
SG10202113199RA (en)	2017-06-01	2021-12-30	Eisai R&D Man Co Ltd	Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
JP7269875B2 (ja)	2017-06-01	2023-05-09	エーザイ・アール・アンド・ディー・マネジメント株式会社	ピラゾロキノリン誘導体を含有するレビー小体病治療剤
RU2019135261A (ru)	2017-06-01	2021-07-09	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Фармацевтическая композиция, содержащая ингибитор pde9
RU2019135834A (ru)	2017-06-01	2021-07-13	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
AU2018281131B2 (en) *	2017-06-08	2022-01-20	Merck Sharp & Dohme Corp.	Pyrazolopyrimidine PDE9 inhibitors
WO2020123271A1 (en) *	2018-12-12	2020-06-18	Merck Sharp & Dohme Corp.	Cyclobutyl pyrazolopyrimidine pde9 inhibitors
CN110339197A (zh) *	2019-06-24	2019-10-18	中山大学	一种防治血管性痴呆的磷酸二酯酶9a抑制剂的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH396924A (de)	1960-05-11	1965-08-15	Ciba Geigy	Verfahren zur Herstellung von 4-Mercapto-pyrazolo(3,4-d)pyrimidinen
DE1147234B (de)	1960-05-11	1963-04-18	Ciba Geigy	Verfahren zur Herstellung von 1-Isopropyl-4-hydroxy-6-benzyl-pyrazolo[3, 4-d]pyrimidin
CH396926A (de)	1960-05-11	1965-08-15	Ciba Geigy	Verfahren zur Herstellung neuer Pyrazolopyrimidine
CH396925A (de)	1960-05-11	1965-08-15	Ciba Geigy	Verfahren zur Herstellung neuer Pyrazolopyrimidine
DE1149013B (de)	1960-05-11	1963-05-22	Ciba Geigy	Verfahren zur Herstellung von 4-Oxo-4, 5-dihydro-pyrazolo-[3, 4-d]Pyrimidinen
CH396927A (de)	1960-05-11	1965-08-15	Ciba Geigy	Verfahren zur Herstellung neuer Pyrazolopyrimidine
US3732225A (en)	1970-07-23	1973-05-08	Squibb & Sons Inc	Pyrazolo(3,4-d)pyrimidine derivatives
US3847908A (en)	1973-03-05	1974-11-12	Squibb & Sons Inc	6-styrylpyrazolo(3,4-d)pyrimidinones and pyrimidines
PT679657E (pt)	1994-04-27	2003-11-28	Novartis Ag	Nucleosidos e oligonucleotidos com grupos 2'-eter
DE69729887T2 (de)	1996-10-16	2005-07-28	ICN Pharmaceuticals, Inc., Costa Mesa	Purin-L-Nukleoside, Analoga und deren Verwendung
DE19709877A1 (de)	1997-03-11	1998-09-17	Bayer Ag	1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
KR20030005197A (ko)	2000-02-18	2003-01-17	샤이어 바이오켐 인코포레이티드	뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
BR0113644A (pt) *	2000-08-30	2003-07-29	Lilly Icos Llc	Usos do inibidor de pde5 no tratamento de enxaqueca
SI1355916T1 (sl)	2001-01-22	2007-04-30	Merck & Co Inc	Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
WO2004009921A2 (en)	2002-07-19	2004-01-29	Mossor David B	Portable shielding system
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
US20040220186A1 (en)	2003-04-30	2004-11-04	Pfizer Inc.	PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
AU2004235915B2 (en) *	2003-05-09	2010-08-05	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
DE10320785A1 (de)	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) *	2003-05-09	2011-10-25	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
WO2005051944A1 (en)	2003-11-21	2005-06-09	University Of Connecticut	Heterocyclyl-substituted oxetanes for the treatment of proliferative or infectious diseases
CA2596424C (en)	2005-02-04	2016-03-29	Millennium Pharmaceuticals, Inc.	Inhibitors of e1 activating enzymes
PT2152712E (pt) *	2007-05-11	2012-02-29	Pfizer	Compostos amino-heterocíclicos
US8648085B2 (en)	2007-11-30	2014-02-11	Boehringer Ingelheim International Gmbh	1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (xx)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	Похідні 1-гетероцикліл-1,5-дигідропіразоло$3,4-d]піримідин-4-ону та їх застосування як модулятори pde9a$производные 1-гетероциклил-1,5-дигидропиразоло$3,4-d] пиримидин-4-она и их применение в качестве модуляторов pde9a
BRPI0918527A2 (pt) *	2008-09-08	2015-12-01	Boehring Ingelheim Internat Gmbh	compostos para o tratamento de disturbios do cns
AU2010230290B2 (en)	2009-03-31	2013-03-14	Boehringer Ingelheim International Gmbh	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators
TW201118099A (en) *	2009-08-12	2011-06-01	Boehringer Ingelheim Int	New compounds for the treatment of CNS disorders
AP2012006631A0 (en) *	2010-08-12	2012-12-31	Boehringer Ingelheim Int	6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors

2012
- 2012-02-09 US US13/369,623 patent/US20130040971A1/en not_active Abandoned
- 2012-02-13 PE PE2013001871A patent/PE20140970A1/es not_active Application Discontinuation
- 2012-02-13 MA MA36160A patent/MA34889B1/fr unknown
- 2012-02-13 JP JP2013552980A patent/JP2014505091A/ja active Pending
- 2012-02-13 SG SG2013061494A patent/SG192756A1/en unknown
- 2012-02-13 AU AU2012217208A patent/AU2012217208A1/en not_active Abandoned
- 2012-02-13 AP AP2013007045A patent/AP2013007045A0/xx unknown
- 2012-02-13 CA CA2827261A patent/CA2827261A1/en not_active Abandoned
- 2012-02-13 KR KR1020137021400A patent/KR20140010036A/ko not_active Withdrawn
- 2012-02-13 PH PH1/2013/501677A patent/PH12013501677A1/en unknown
- 2012-02-13 BR BR112013020605A patent/BR112013020605A2/pt not_active IP Right Cessation
- 2012-02-13 EP EP20120705246 patent/EP2675807B1/en active Active
- 2012-02-13 EA EA201300908A patent/EA023574B1/ru not_active IP Right Cessation
- 2012-02-13 MX MX2013009343A patent/MX2013009343A/es active IP Right Grant
- 2012-02-13 WO PCT/EP2012/052378 patent/WO2012110440A1/en not_active Ceased
- 2012-02-13 TW TW101104596A patent/TW201245199A/zh unknown
- 2012-02-13 CN CN2012800177072A patent/CN103459397A/zh active Pending
- 2012-02-13 AR ARP120100472A patent/AR085219A1/es unknown
2013
- 2013-07-18 IL IL227526A patent/IL227526A0/en unknown
- 2013-07-29 TN TNP2013000324A patent/TN2013000324A1/fr unknown
- 2013-08-12 CL CL2013002341A patent/CL2013002341A1/es unknown
- 2013-08-26 EC ECSP13012852 patent/ECSP13012852A/es unknown
- 2013-09-12 CO CO13216891A patent/CO6791616A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
ECSP13012852A (es)	2014-09-30
MA34889B1 (fr)	2014-02-01
PH12013501677A1 (en)	2018-04-11
SG192756A1 (en)	2013-09-30
CN103459397A (zh)	2013-12-18
BR112013020605A2 (pt)	2016-10-18
EP2675807A1 (en)	2013-12-25
CA2827261A1 (en)	2012-08-23
EP2675807B1 (en)	2015-04-22
CO6791616A2 (es)	2013-11-14
EA201300908A1 (ru)	2014-01-30
AU2012217208A1 (en)	2013-08-01
PE20140970A1 (es)	2014-08-03
AR085219A1 (es)	2013-09-18
TN2013000324A1 (en)	2015-01-20
KR20140010036A (ko)	2014-01-23
TW201245199A (en)	2012-11-16
WO2012110440A1 (en)	2012-08-23
MX2013009343A (es)	2013-10-01
IL227526A0 (en)	2013-09-30
EA023574B1 (ru)	2016-06-30
CL2013002341A1 (es)	2014-04-04
US20130040971A1 (en)	2013-02-14
JP2014505091A (ja)	2014-02-27
WO2012110440A9 (en)	2013-03-14

Publication	Publication Date	Title
IL227526A0 (en)	2013-09-30	Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors
AP2012006631A0 (en)	2012-12-31	6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
IL257410A (en)	2018-04-30	Pyrazolo [1, 5 – a ] pyrimidines as antiviral agents
LT2857404T (lt)	2017-11-10	Imidazo[1,2-b]piridazino dariniai, kaip kinazės inhibitoriai
PT2794611T (pt)	2017-12-06	Pirazolo[1,5-a]pirimidinas como agentes antivirais
ZA201307839B (en)	2015-02-25	Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
IL214436A0 (en)	2011-09-27	1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
IL229606A0 (en)	2014-01-30	Pyrazolone [3, 4-d] pyrimidine compounds and their use as 2pde inhibitors and/or 4a3 cyp inhibitors
PT2935274T (pt)	2018-12-05	Derivados de 3-oxo-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3- a]pirimidina para o tratamento de doenças respiratórias
ZA201405070B (en)	2016-03-30	1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
AP2013007147A0 (en)	2013-09-30	Use of substituted 2,3-dihydroimidazo[1,2-C]quinyzolines
EP2739627A4 (en)	2015-01-21	2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
ZA201406323B (en)	2016-08-31	Triazolo[4,5-d]pyrimidine derivatives
ZA201307511B (en)	2016-08-31	Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
ZA201403441B (en)	2015-08-26	[1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid
PT2694513E (pt)	2015-04-09	Derivados de pirazolopirimidina
ZA201307085B (en)	2015-04-29	Thieno [2,3-d] pyrimidine derivatives and their use to treat arrhythmia
SG10201602846TA (en)	2016-05-30	4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and use as antiviral agents